Better Therapeutics- Tradeable Rights - March 2021 Accounts Payable

Better Therapeutics- Tradeable Rights - March 2021 posts a accounts payable of $2.3M as of September 2023. That compares with $1.3M in the prior-year period — up 83.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Better Therapeutics- Tradeable Rights - March 2021's accounts payable was $1.3M. The latest reading is $2.3M — a 83.9% year-over-year increase (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of Better Therapeutics- Tradeable Rights - March 2021's financial statement story. At $2.3M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MCADR's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Better Therapeutics- Tradeable Rights - March 2021's other metric pages and overview cover the third.